Arcus appoints Richard Markus as CMO; Dimitry Nuyten departs Jan 31, 2025

Arcus Biosciences, Inc.

Richard Markus, M.D., Ph.D., named Chief Medical Officer, effective January 31, 2025.
Dimitry Nuyten, M.D., Ph.D., will depart from Arcus on the same date.
Dr. Nuyten eligible for lump-sum severance of 12 months base salary, 12 months COBRA, and 2024 bonus.
Separation agreement details described; final agreement to be filed after execution.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Markus

Chief Medical Officer

RCUS · Arcus Biosciences, Inc.

Effective: 2025-01-31
Filed: January 21, 2025, 6:59 PM ET

Richard Markus, M.D., Ph.D. has been appointed as the Company’s Chief Medical Officer, effective January 31, 2025

Departed

Dimitry Nuyten

Chief Medical Officer

RCUS · Arcus Biosciences, Inc.

Effective: 2025-01-31
Successor: Richard Markus
Filed: January 21, 2025, 6:59 PM ET

Dimitry Nuyten, M.D., Ph.D. will depart from the Company on January 31, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Markus was appointed as Chief Medical Officer at Arcus Biosciences, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Richard Markus, M.D., Ph.D. has been appointed as the Company’s Chief Medical Officer, effective January 31, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dimitry Nuyten departed as Chief Medical Officer at Arcus Biosciences, Inc..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

Dimitry Nuyten, M.D., Ph.D. will depart from the Company on January 31, 2025

View on SEC.gov

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001724521-25-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.